1. Home
  2. WAY vs IOVA Comparison

WAY vs IOVA Comparison

Compare WAY & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Waystar Holding Corp.

WAY

Waystar Holding Corp.

HOLD

Current Price

$24.25

Market Cap

4.8B

Sector

N/A

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$3.93

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WAY
IOVA
Founded
1999
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
2.1B
IPO Year
2023
2008

Fundamental Metrics

Financial Performance
Metric
WAY
IOVA
Price
$24.25
$3.93
Analyst Decision
Strong Buy
Buy
Analyst Count
16
10
Target Price
$37.56
$9.11
AVG Volume (30 Days)
3.0M
16.9M
Earning Date
05-20-2026
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
569.23
14.84
EPS
0.61
N/A
Revenue
$1,099,278,000.00
N/A
Revenue This Year
$18.35
$49.14
Revenue Next Year
$10.53
$51.69
P/E Ratio
$40.38
N/A
Revenue Growth
16.50
N/A
52 Week Low
$21.13
$1.64
52 Week High
$41.96
$5.63

Technical Indicators

Market Signals
Indicator
WAY
IOVA
Relative Strength Index (RSI) 40.59 52.57
Support Level $21.13 $1.99
Resistance Level $26.29 $4.34
Average True Range (ATR) 1.13 0.50
MACD 0.03 -0.00
Stochastic Oscillator 11.89 28.72

Price Performance

Historical Comparison
WAY
IOVA

About WAY Waystar Holding Corp.

Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. Its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for solutions extends throughout the United States and includes Puerto Rico and other USA Territories.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: